期刊文献+

多沙唑嗪和美托洛尔对腹主动脉缩窄致高血压大鼠血管重塑的影响 被引量:6

Effect of doxazosin and metoprolol on vascular remodeling in rats with hypertension induced by abdominal aorta coarctation
下载PDF
导出
摘要 目的观察多沙唑嗪及美托洛尔对腹主动脉缩窄(AAC)诱导的大鼠血管重塑的影响。方法采用AAC法成功建立血管重塑大鼠模型。2周后每天ig给予多沙唑嗪10 mg·kg-1或美托洛尔20 mg·kg-1,连续6周。采用颈总动脉插管测量大鼠的平均动脉压;采用HE染色和图像分析仪检测大鼠主动脉中膜厚度、中膜面积和中膜厚度与管腔内径比值;Masson染色检测纤维化;Western蛋白印迹法检测胶原蛋白和纤连蛋白表达。结果与假手术组血压(17.6±0.5)k Pa相比,模型组大鼠血压(23.3±0.7)k Pa显著升高(P<0.05),给予多沙唑嗪〔(20.5±0.7)k Pa〕或美托洛尔〔(19.0±0.4)k Pa〕均可有效降低血压(P<0.05)。HE染色结合图像分析仪分析发现,模型组大鼠血管中膜厚度、中膜面积及中膜厚度与血管内径比值较假手术组分别升高39.5%,46.4%和27.0%(P<0.05),给予多沙唑嗪或美托洛尔使血管的中膜厚度分别下降16.0%和26.1%(P<0.05),中膜面积分别下降22.8%和29.1%(P<0.05),中膜厚度与血管内径比值分别下降17.0%和26.0%(P<0.05)。Masson染色结果显示,与假手术组相比,模型组大鼠血管组织胶原蛋白的沉积增多,血管出现纤维化;而给予多沙唑嗪或美托洛尔可以缓解高血压诱导的纤维化发生。Western蛋白印迹结果显示,模型组大鼠血管组织中胶原蛋白和纤连蛋白的表达明显增加(P<0.05),而多沙唑嗪组和美托洛尔组较模型组胶原蛋白和纤连蛋白表达显著下降(P<0.05)。结论多沙唑嗪和美托洛尔可能通过抑制去甲肾上腺素与其特异性受体结合,从而选择性地阻断去甲肾上腺素对血管的诱导作用,逆转高血压诱导的血管重塑的发生。 OBJECTIVE To investigate the effect of doxazosin(DOX) and metoprolol( MET) on vascular remodeling in rats with abdominal aorta coarctation (AAC). METHODS An animal model was established by AAC. Two weeks later, the rats were treated with DOX (10 mg.kg-1 per day) or MET (20 mg.kg-1 per day) for six weeks. Blood pressure was measured using carotid artery intubation with a MP150 polygraph. The media thickness, wall cross-sectional area and thickness / internal diameter ratio were calculated by morphometry. Vascular fibrosis was evaluated by Masson′s trichrome staining. The collagen and fibronectin expression in vascules was measured by Western blotting. RESULTS Compared with the sham group 〔(17.6±0.5)kPa〕, the mean arterial blood pressure in the model group〔(23.3±0.7)kPa〕 was significantly increased(P〈0.05), but was lowered by DOX 〔(20.5±0.7)kPa〕 and MET 〔(19.0±0.4) kPa〕 (P〈0.05). Moreover, HE staining showed that tunica media thickness, artery vessel area and thickness / inner diameter in the model group were increased by 39.5%, 46.4% and 27.0%(P〈0.05), respectively. The tunica media thickness was decreased by 16.0% and 26.1%( P〈0.05), respectively, the artery vessel area by 22.8% and 26.1%(P〈0.05), respectively, and the thick-ness / inner diameter by 17.0% and 26.0%( P〈0.05) when the rats were treated with DOX and MET. Masson staining showed that the collagen accumulation in vascules increased, suggesting that AAC induced fibrosis. Meanwhile, vascular fibrosis induced by AAC was also reduced by MET or DOX. Western blotting also proved that the increase of collagen and fibronectin induced by AAC could be attenuated by DOX and MET(P〈0.05). CONCLUSION DOX and MET are effective in suppressing the role of norepi-nephrine in vassels, which can attenuate AAC-induced vassels remodeling by preventing the binding between norepinephrine and adrenoceptors.
出处 《中国药理学与毒理学杂志》 CAS CSCD 北大核心 2015年第2期208-212,共5页 Chinese Journal of Pharmacology and Toxicology
基金 国家重点基础研究发展规划(2011CB505106) 天津市自然科学重点基金(10JCZDJC19300)~~
关键词 血管重塑 高血压 多沙唑嗪 美托洛尔 vascular remodeling hypertension doxazosin metroprolol
  • 相关文献

参考文献2

二级参考文献42

  • 1Kalmes A, Vesti BR, Daum G, Abraham JA, Clowes AW. Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor. Circ Res 2000; 87: 92-8.
  • 2Duan C, Bauchat JR, Hsieh T. Phosphatidylinositol 3-kinase is required for insulin-like growth factor-I-induced vascular smooth muscle cell proliferation and migration. Circ Res 2000; 86: 15-23.
  • 3Chai YC, Howe PH, Dicorleto PE, Chisolm GM. Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells. Evidence for release of fibroblast growth factor-2. J Biol Chem 1996; 271: 17791-7.
  • 4Nakaki T, Nakayama M, Yamamoto S, Kato R. Alpha 1-adrenergic stimulation and beta 2-adrenergic inhibition of DNA synthesis in vascular smooth muscle cells. Mol Pharmacol. 1990; 37: 30-6.
  • 5Delling U, Tureckova J, Lim HW, De Windt LJ, Rotwein P, Molkentin JD. A calcineurin-NFATc3-dependent pathway regulates skeletal muscle differentiation and slow myosin heavy-chain expression. Mol Cell Biol ,2000; 20:6600-11.
  • 6Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93: 215-28.
  • 7GraefIA, Chen F, Chen L, Kuo A, Crabtree GR. Signals transduced by Ca^2+/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell 2001; 105: 863-75.
  • 8Fiedler B, Lohmann SM, Smolenski A, Linnemuller S, Pieske B, Schroder F, et al. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci USA 2002; 99:11363-8.
  • 9Yellaturu CR, Ghosh SK, Rao RK, Jennings LK, Hassid A, Rao GN. A potential role for nuclear factor of activated T-cells in receptor tyrosine kinase and G-protein-coupled receptor agonist- induced cell proliferation. Biochem J 2002; 368:183-90.
  • 10Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FKS06 complexes. Cell 1991; 66: 807-15.

共引文献79

同被引文献48

引证文献6

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部